JAZZ 8-K 2026-09-23
Jazz Pharmaceuticals plc (JAZZ) 8-K dated 2026-09-23 — accession 0001193125-26-399425.
Jazz Pharmaceuticals plc (JAZZ) is a biotechnology company listed on US.
Jazz Pharmaceuticals plc filed a 8-K on 2026-09-23. Accession 0001193125-26-399425.
This 8-K covers: Material agreement (Item 1.01), New debt obligation (Item 2.03), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported JAZZ revenue for 2025-12-31 was $4.27B. Net income was -$356.1M. Revenue was up 4.9% from 2024-12-31 to 2025-12-31. JAZZ currently screens at market cap $14.97B.
Not investment advice. The JAZZ SEC hub lists recent forms. The stock page is the research view.